StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$161.52+0.73 (+0.45%)

Close on Nov 2, 2026Market cap $308.21BP/E 22.6Yield –

Novartis Financing Cash Flow (annual) by Year

Financing Cash Flow (annual) ($M)

Novartis Financing Cash Flow (annual): -$14,867M in FY2025, up 26.6% from a year earlier.

Latest, FY2025
-14,867
Period ended Dec 31, 2025
Change on a year earlier
+26.6%
-11,742 in FY2024
History
11 years
Since FY2015
Sources
9
Documents cited below

Where the FY2025 figure comes from

Source: Novartis 20-F (0001114448-26-000004, filed 2026-02-04) ↗

Reported in Postgres DB.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Novartis Financing Cash Flow (annual) ($M), annual FY2015–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/db-cf-financing

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.